IRD
Opus Genetics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.67
+0.55%Year over year
Reported trailing growth
- Revenue
- -36.1%
- EBITDA
- —
- EBIT
- +22.0%
- EPS
- +27.8%
- Free cash flow
- -27.8%
- Operating cash flow
- -27.8%
Forward estimates
Based on analyst estimates
- Revenue
- +27.6%
- EBITDA
- +42.1%
- EPS
- +54.6%
Three-year CAGR
- Revenue
- -29.1%
- EBITDA
- +16.4%
- EBIT
- +37.8%
- Net income
- +13.8%
- EPS
- +62.8%
- Free cash flow
- -37.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026